LBRX (LB Pharmaceuticals) 12-1 Month Momentum %: N/A% (As of Jul. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LBRX LB Pharmaceuticals Inc LBRX
12 GF Score
Price $34.72
! 1 Warning Sign
View Full Analysis

What is LB Pharmaceuticals 12-1 Month Momentum %?

LB Pharmaceuticals LBRX -3.30% 12 12-1 Month Momentum % is N/A% as of Jul. 23, 2026. GuruFocus rates LBRX with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,358 Biotechnology companies, LB Pharmaceuticals ranks worse than 73637.63% on this metric.

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-07-23), LB Pharmaceuticals's 12-1 Month Momentum % is N/A%.

The industry rank for LB Pharmaceuticals's 12-1 Month Momentum % or its related term are showing as below:

LBRX's 12-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -17.135
* Ranked among companies with meaningful 12-1 Month Momentum % only.

LB Pharmaceuticals  (NAS:LBRX) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

LB Pharmaceuticals 12-1 Month Momentum % Related Terms

LBRX
12GF Score
LB Pharmaceuticals Inc LBRX
12-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LB Pharmaceuticals  (NAS:LBRX) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 12-1 Month Momentum % →
What does a 12-1 Month Momentum % of N/A% mean?
LB Pharmaceuticals (LBRX) has a 12-1 Month Momentum % of N/A% as of Jul. 23, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on LB Pharmaceuticals and its competitors. According to the industry distribution chart, LB Pharmaceuticals ranks #999999 out of 1358 companies in the Biotechnology industry.
Is LB Pharmaceuticals' 12-1 Month Momentum % too high?
LB Pharmaceuticals' current 12-1 Month Momentum % is N/A%. Based on the distribution chart, LB Pharmaceuticals ranks #999999 out of 1358 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, LB Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LB Pharmaceuticals' 12-1 Month Momentum % compare to MRVI and SLDB?
According to the Biotechnology industry distribution chart, LB Pharmaceuticals ranks #999999 out of 1358 companies for 12-1 Month Momentum %. This places LB Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on LB Pharmaceuticals and its competitors. LB Pharmaceuticals's current 12-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LB Pharmaceuticals stock overvalued right now?
LB Pharmaceuticals (LBRX) has a current 12-1 Month Momentum % of N/A%. The current 12-1 Month Momentum % is N/A%. LB Pharmaceuticals' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For LB Pharmaceuticals (LBRX), the current 12-1 Month Momentum % is N/A% as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LB Pharmaceuticals Business Description

Address One Pennsylvania Plaza, Suite 1025, New York, NY, USA, 10119
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
12GF Score

Get the complete analysis for LBRX

12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$34.72
Price